Search

everythinglearnresearchcommunity

for

Search:↓

Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.

Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.

Denosumab treatment for osteoporosis can cause hair loss.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Etanercept may not prevent alopecia areata from coming back.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.